Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prescient Medical achieves milestone in vProtect Luminal Shield trial
According to the company, the shield successfully crossed all target lesions and was safely implanted in all 30 patients, with a technical success rate of 100%. No procedural
According to the company, the shield successfully crossed all target lesions and was safely implanted in all 30 patients, with a technical success rate of 100%. No procedural
Michael Adams, president and CEO of AdvanSource Biomaterials, said: “We sincerely appreciate Eric’s contributions since he joined the company in October 2005 as a seasoned financial executive, including
The intranasal method was developed by William Frey II, senior director of HealthPartners Research Foundation’s Alzheimer’s Research Center, and his colleagues. According to Sanomune, the new method allows
Together, HemCon and ProMetic will develop and validate a sterile, single-use antibody capture device for the removal of isoagglutinin antibodies. The exclusive agreement covers the development of a
According to the Translational Genomics Research Institute (TGen), Safeway’s donation represents a 37% increase from the $500,000 that the company gave TGen last year. The contributions both years
With ClearTrial Portfolio Planning, available in the enterprise edition of ClearTrial version 2.7, clinical development organizations can now roll up protocol-level study plans into portfolio-level forecasts, providing instant
The technology utilizes a gas ionization process producing a stable thin focused beam of ionized gas that can be controlled in a range of temperatures and intensities, providing
The union between the two CROs will significantly improve Tigermed’s clinical data management serviceability and broaden MacroStat’s business line, said Tigermed. Ye Xiaoping, CEO and founder of Tigermed,
The collaboration agreement focuses on the operation of the facility, as well as the management of samples deposited by Duke University, and its clients and collaborators, including samples
In this multi-center, randomized, open-label Phase II study, clinical effect of a combination of carboplatin, etoposide and obatoclax will be compared to the standard chemotherapeutic therapy of carboplatin